Uremic Toxins and Oral Adsorbents

Therapeutic Apheresis and Dialysis

Volumn 15, Issue 2, 2011, Pages 132-134

  Goto, Shunsuke ^a   Yoshiya, Kunihiko ^b   Kita, Tomoyuki ^c   Fujii, Hideki ^a   Fukagawa, Masafumi ^d  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Hara Genitourinary Hospital   (Japan)

^c Sakai Rumi Clinic   (Japan)

^d TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AST 120; Indoxyl sulfate; Sevelamer hydrochloride; Uremic toxin

Indexed keywords

AST 120; CALCIUM ACETATE; HOMOCYSTEINE; INDICAN; INDOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARA CRESOL; PHOSPHATE BINDING AGENT; SEVELAMER; UREMIC TOXIN;

ADSORPTION; AMINO ACID BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD LEVEL; BLOOD VESSEL CALCIFICATION; BONE TURNOVER; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DRUG BINDING; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; UREMIA;

ADMINISTRATION, ORAL; ANIMALS; CARBON; CHELATING AGENTS; HUMANS; INDICAN; KIDNEY FAILURE, CHRONIC; MICE; OXIDES; POLYAMINES; PROTEIN BINDING; UREMIA;

EID: 79953050849     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2010.00891.x     Document Type: Article

References (23)

1. Vanholder R, De Smet R, Glorieux G etal. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-43.
2. Vanholder R, Baurmeister U, Brunet P etal. A bench to bedside view of uremic toxins. J Am Soc Nephrol 2008;19:863-70.
3. Evenepoel P, Meijers BK, Bammens BR, Verbeke K. Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl 2009;76:S12-9.
4. Miyazaki T, Aoyama I, Ise M, Seo H, Niwa T. An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGF-beta1 in uraemic rat kidneys. Nephrol Dial Transplant 2000;15:1773-81.
5. Niwa T, Miyazaki T, Hashimoto N etal. Suppressed serum and urine levels of indoxyl sulfate by oral sorbent in experimental uremic rats. Am J Nephrol 1992;12:201-6.
6. Niwa T, Ise M, Miyazaki T, Meada K. Suppressive effect of an oral sorbent on the accumulation of p-cresol in the serum of experimental uremic rats. Nephron 1993;65:82-7.
7. Yamagishi S, Nakamura K, Matsui T, Inoue H, Takeuchi M. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders. Med Hypotheses 2007;69:666-8.
8. Akizawa T, Asano Y, Morita S etal. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis 2009;54:459-67.
9. Schulman G, Agarwal R, Acharya M, Berl T, Blumenthal S, Kopyt N. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. Am J Kidney Dis 2006;47:565-77.
10. Ueda H, Shibahara N, Takagi S, Inoue T, Katsuoka Y. AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis. Ren Fail 2008;30:856-60.
11. Nakamura T, Kawagoe Y, Matsuda T etal. Oral adsorbent AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. Kidney Blood Press Res 2004;27:121-6.
12. Fujii H, Nishijima F, Goto S etal. Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dial Transplant 2009;24:2089-95.
13. Iwasaki-Ishizuka Y, Yamato H, Nii-Kohno T, Kurokawa K, Fukagawa M. Down-regulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. Nephrol Dial Transplant 2005;20:1904-11.
14. Iwasaki Y, Yamato H, Nii-Kono T etal. Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats. Nephrol Dial Transplant 2006;21:2768-74.
15. Goto S, Fujii H, Hamada Y, Yoshiya K, Fukagawa M. Association between indoxyl sulfate and skeletal resistance in hemodialysis patients. Ther Apher Dial 2010;14:417-23.
16. Wilkes BM, Reiner D, Kern M, Burke S. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Clin Nephrol 1998;50:381-6.
17. Braunlin W, Zhorov E, Guo A etal. Bile acid binding to sevelamer HCl. Kidney Int 2002;62:611-19.
18. Chertow GM, Raggi P, Chasan-Taber S etal. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004;19:1489-96.
19. Qunibi W, Moustafa M, Muenz LR etal. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008;51:952-65.
20. Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005;149:820-5.
21. DeSmet R, Thermote F, Lameire N etal. Sevelamer hydrochloride (Renagel) adsorbs the uremic compounds indoxyl sulfate, indole and p-cresol (Abstract). J Am Soc Nephrol 2004;15.
22. Phan O, Ivanovski O, Nguyen-Khoa T etal. Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 2005;112:2875-82.
23. Goto S, Fujii H, Kim JI, Fukagawa M. Homocysteine and folic acid levels in hemodialysis patients treated with sevelamer hydrochloride. Clin Nephrol 2010;73:420-5.